20
total announcements
ASTEC.NS · 15 min delayed
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange about the publication of unaudited financial results for the quarter ended June 30, 2026, in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange regarding 'Adoption of Annual Report 2025-26 by the Shareholders at the AGM held on 31st July, 2026.' The company has adopted its annual report for the financial year 2025-26 and has also re-appointed Mr. Ashok V. Hiremath as a director. The AGM was held through video conferencing and the results of the voting will be declared within 2 working days.
Astec LifeSciences Limited
Astec LifeSciences Limited has held its 32nd Annual General Meeting (AGM) on July 31, 2026, where the company's financial statements for the year ended March 31, 2026, were adopted, and the results of the voting on various resolutions were declared.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange about General Updates, including the outcome of the 32nd Annual General Meeting (AGM) and the adoption of financial statements for the Financial Year ended 31 March, 2026. The AGM was held on 31 July, 2026, and the results of the voting will be declared within 2 working days.
Astec LifeSciences Limited
Astec LifeSciences Limited has announced its Q1 FY27 financial results, reporting a consolidated total income of ₹84.3 crore, a 8.0% decline from ₹91.6 crore in Q1FY26. The company achieved EBITDA breakeven in the quarter compared to an EBITDA loss of ₹10.5 crore in the same period last year, despite lower revenues. Revenue from Enterprise Products grew 42% YoY to ₹51.8 crore in Q1 FY27, compared to ₹36.5 crore in Q1 FY26.
Astec LifeSciences Limited
Astec LifeSciences Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a loss of Rs. 1,873.82 lakhs before tax and Rs. 1,870.73 lakhs after tax. The company's revenue from operations was Rs. 8,356.43 lakhs, with a total income of Rs. 8,429.17 lakhs. The company has also noted the limited review reports of the statutory auditors, which are with an unmodified opinion.
Astec LifeSciences Limited
Astec LifeSciences Limited has announced its unaudited financial results for the quarter ended June 30, 2026, showing a loss of Rs. 1,873.82 lakhs before tax and Rs. 1,870.73 lakhs after tax. The company's revenue from operations was Rs. 8,356.43 lakhs, with a net loss of Rs. 1,861.72 lakhs for the quarter.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing on the stock exchange.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange about the publication of a newspaper advertisement regarding the 32nd Annual General Meeting (AGM) and the extension of a special window for re-lodging physical share transfer requests. Shiva Texyarn Limited has also published a notice for the extension of a special window for re-lodging physical share transfer requests.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange regarding 'Closure of Register of Members and Share Transfer Books' for the purpose of the 32nd Annual General Meeting.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange regarding its Annual General Meeting and Annual Report 2025-26.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 31, 2026 and Annual Report 2025-26.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange regarding Change in Director(s) of the company, with the appointment of four new directors, including two non-executive and two executive directors, and the approval of related party transactions with Godrej Agrovet Limited and Godrej Industries Limited.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange regarding the outcome of the postal ballot and the disclosure of the scrutinizer's report and voting results. The company has passed the resolutions for the appointment of new directors, including Mr. Vishal Sharma, Mr. Burjis N. Godrej, Mr. Arijit Mukherjee, and Mr. Mathew Eipe, and the approval of related party transactions with Godrej Agrovet Limited and Godrej Industries Limited.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange regarding the outcome of the postal ballot and disclosure of the Scrutinizer's Report & Voting Results. The company has passed the resolutions for the appointment of new directors, including Mr. Vishal Sharma, Mr. Burjis N. Godrej, Mr. Arijit Mukherjee, and Mr. Mathew Eipe, and related party transactions with Godrej Agrovet Limited and Godrej Industries Limited.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange about postal ballot. The company has passed several resolutions, including the appointment of new directors and approval of related party transactions.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window will be closed from 1st July, 2026 till 48 hours after the declaration of the Unaudited Financial Results for the Quarter ending on 30th June, 2026.
Astec LifeSciences Limited
Astec LifeSciences Limited has informed the Exchange about the publication of a public notice regarding the 32nd Annual General Meeting (AGM) to be held on July 31, 2026, through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
Astec LifeSciences Limited
Godrej Agrovet Limited, as part of the promoter group of Astec LifeSciences Limited, submitted its annual declaration under SEBI Takeover Regulations. The declaration confirms that the promoter group, along with persons acting in concert, did not encumber (pledge) any of their shareholding in Astec LifeSciences Limited during the financial year 2025-26. This filing is a routine compliance requirement, confirming stable promoter holdings.
Astec LifeSciences Limited
Astec LifeSciences Limited announced a disclosure filed by Ashok V. Hiremath under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This specific regulation typically relates to the release of previously encumbered or pledged shares by promoters or persons in control of a company. For investors, this suggests that a portion of promoter shares, which may have been used as collateral, are no longer pledged. This could be viewed as a positive sign, potentially indicating reduced financial leverage or risk for the promoter and the company.